Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Quetiapine monotherapy in bipolar II depression: combined data from four large, randomized studies. International journal of bipolar disorders Young, A. H., Calabrese, J. R., Gustafsson, U., Berk, M., McElroy, S. L., Thase, M. E., Suppes, T., Earley, W. 2013; 1: 10-?

Abstract

Despite being present in up to 1% of the population, few controlled trials have examined the efficacy of treatments for bipolar II depression. Pooled data are presented from four placebo-controlled studies (BOLDER I [5077US/0049] and II [D1447C00135]; EMBOLDEN I [D1447C00001] and II [D1447C00134]) that evaluated the efficacy of quetiapine monotherapy for depressive episodes in patients with bipolar II disorder.All studies included an 8-week, double-blind treatment phase in which patients were randomly assigned to treatment with quetiapine 300 mg/day, quetiapine 600 mg/day, or placebo. Outcome measures included the change from baseline in MADRS total score at week 8, effect sizes, and MADRS response and remission rates.Improvements in mean MADRS total scores from baseline to week 8 were significantly greater with quetiapine 300 and 600 mg/day (-15.58 [n?=?283] and -14.88 [n?=?289]; p?

View details for DOI 10.1186/2194-7511-1-10

View details for PubMedID 25505677

View details for PubMedCentralID PMC4230312